| Name | RUA Life Sciences |
|---|---|
| Epic | RUA |
| Isin | GB0033360586 |
| Industry | Medical Equipment and Services |
| Latest share price | 13.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £8.07 | Debt ratio | n/a |
| Shares in issue | 62.06 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -27.97 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -4.29 | 52-week high / low | 8.75p / 14.75p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | RUA Life Sciences |
|---|---|
| Address | 163 Bath Street, Glasgow, United Kingdom, G2 4SQ |
| Telephone | |
| Website | http://rualifesciences.com/ |
| Director | Position |
|---|---|
| Mr Lachlan Smith | CFO |
| Mr William D Brown | Chairman |
| Mr John McKenna | Non-Executive Director |
| Mr John Louis Ely | Independent Non-Executive Director |
| Mr Ian Ardill | Independent Non-Executive Director |
| Mr Geoffrey Alan Berg | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/03/24 | 31/03/23 | 31/03/22 |
| Intangible asssets and goodwill | 0.72 | 0.77 | 0.82 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 3.18 | 3.51 | 3.42 |
| Inventory / work in progress | 0.11 | 0.08 | 0.12 |
| Trade and other receivables | 0.95 | 0.59 | 1.12 |
| Cash and equivalents | 3.93 | 1.48 | 2.96 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 8.17 | 5.66 | 7.63 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 0.55 | 0.41 | 0.51 |
| Long term liabilities | 0.43 | 0.57 | 0.53 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.99 | 0.98 | 1.04 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 7.18 | 4.68 | 6.58 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 3.1 | 1.11 | 1.11 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -19.98 | -18.55 | -16.54 |
| Share premium account | 13.71 | 11.73 | 11.73 |
| Total equity | 7.18 | 4.68 | 6.58 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -1.94 | -2.31 | -2.35 |
| Pre-tax profit | -2.02 | -2.32 | -2.36 |